Clinical Trial Update: Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis [Phase 4]

View source ↗

Summary

Clinical trial evaluating omalizumab for chronic sinusitis was withdrawn after Phase 4.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sinusitis

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Chronic Sinusitis | Phase 4 | Status: WITHDRAWN